| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 501,00 | 505,00 | 21:12 | |
| 501,00 | 505,00 | 21:00 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 506,00 | 1 | |||
| 505,60 | 1 | |||
| 505,20 | 14 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/ix1.htm [/URL] | ||||
| 1 | 505,00 | |||
| 1 | 504,60 | |||
| 1 | 504,20 | |||
| 13 | 502,20 | |||
| 1.049 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.065 | 0,015 | 16 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | -8,40 -1,64 % | 1 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Is IDEXX Laboratories Stock Outperforming the S&P 500? | 3 | Barchart.com | ||
| IDEXX LABORATORIES Aktie jetzt für 0€ handeln | |||||
| Fr | If You Invested $1000 In IDEXX Laboratories Stock 10 Years Ago, You Would Have This Much Today | 2 | Benzinga.com | ||
| 02.03. | IDEXX Laboratories: Wachstumsstrategie durch Innovation auf Investorenkonferenz vorgestellt | 4 | Investing.com Deutsch | ||
| 23.02. | Here's What Analysts Are Saying About IDEXX Laboratories (IDXX) | 4 | Insider Monkey | ||
| 20.02. | IDEXX LABORATORIES INC /DE - 10-K, Annual Report | 3 | SEC Filings |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | GlobeNewswire (Europe) | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 14:00 | MetaVia Inc.: MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control | PR Newswire | 16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults
CAMBRIDGE, Mass., March 18, 2026... ► Artikel lesen | |
| 14:10 | VIVUS B.V.: VIVUS Confirms QSIVA Price Reduction Is Now Effective Across Nordics and Poland | GlobeNewswire (Europe) | - The lowered pricing structure is now available for 101.82 EUR per bottle at pharmacies throughout Finland
AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical... ► Artikel lesen | |
| 15:10 | LeonaBio-Aktie: +167% nach NBC-Tipp | sharedeals.de | Die deutschsprachige Biotech-Szene rund um den No Brainer Club und Chefanalyst Maximilian Ruth hat erneut geliefert. Während die breite Masse erst jetzt auf die Aktie von LeonaBio aufmerksam wird, waren... ► Artikel lesen | |
| 17:24 | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | AFX News | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen |